Which Weight Loss Injection is FDA Approved? Understanding Your Options

With the rapid growth of injectable weight loss medications, it can be difficult to know which products are genuinely FDA-approved and which are not. This distinction matters enormously: FDA approval requires rigorous clinical trial evidence for both safety and efficacy — something that most weight loss products on the market do not have.

This article covers every FDA-approved injectable option for weight management as of 2025, explaining how each works, who it's approved for, and what clinical trial results show.

What FDA Approval Actually Means

The FDA approves medications through a multi-phase clinical trial process that typically takes 7–10 years and involves thousands of participants. For a weight management drug to receive approval, it must demonstrate:

Efficacy: Produces significantly greater weight loss than placebo in randomised controlled trials
Safety: Acceptable side effect profile that does not outweigh benefits
Manufacturing standards: Consistent, high-quality production

FDA approval is not the same as "recommended for everyone" — it means that for a specific population with defined characteristics, the evidence supports the drug's use under medical supervision.

Currently FDA-Approved Weight Loss Injections

1. Semaglutide 2.4mg (Wegovy) — Approved June 2021

Drug class: GLP-1 receptor agonist

How it works: Mimics the hormone GLP-1, which slows gastric emptying, reduces appetite through brain receptors in the hypothalamus, and improves insulin sensitivity.

Clinical evidence (STEP trials):

Average weight loss: 14.9–17.4% of body weight over 68 weeks
Compared to placebo: participants lost approximately 12–13% more body weight
~70% of participants achieved ≥5% weight loss; ~50% achieved ≥15%

Who qualifies:

Adults with BMI ≥30, OR
BMI ≥27 with at least one weight-related condition (type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease)

Dosing: Weekly injection, subcutaneous; titrated from 0.25mg up to 2.4mg over 16–20 weeks

Common side effects: Nausea (very common, especially early), vomiting, diarrhoea, constipation, fatigue. Usually diminish after the first 4–8 weeks.

2. Tirzepatide 2.5–15mg (Zepbound) — Approved November 2023

Drug class: Dual GIP/GLP-1 receptor agonist

How it works: Activates both GIP and GLP-1 receptors simultaneously. This dual mechanism appears to produce greater appetite suppression and metabolic effects than GLP-1 alone.

Clinical evidence (SURMOUNT trials):

Average weight loss: 20.9% of body weight at 15mg dose over 72 weeks — the highest average weight loss ever demonstrated in a pharmaceutical trial for obesity
57% of participants achieved ≥20% weight loss at the highest dose

Who qualifies: Same criteria as Wegovy (BMI ≥30 or ≥27 with weight-related condition)

Dosing: Weekly injection; titrated from 2.5mg up to 15mg over 20 weeks

Note: Tirzepatide is also approved as Mounjaro for type 2 diabetes management at overlapping doses, but Zepbound is specifically approved for weight management.

Common side effects: Similar to semaglutide — nausea, diarrhoea, vomiting, constipation, decreased appetite. Typically most pronounced during dose escalation.

3. Liraglutide 3.0mg (Saxenda) — Approved December 2014

Drug class: GLP-1 receptor agonist

How it works: Same mechanism as semaglutide but shorter-acting, requiring daily rather than weekly injection.

Clinical evidence (SCALE trials):

Average weight loss: 8.0% of body weight over 56 weeks
Approximately 4–5% greater loss than placebo

Who qualifies: Same BMI criteria as above; also approved for adolescents aged 12+ with initial BMI ≥95th percentile

Dosing: Daily injection; titrated over 5 weeks from 0.6mg to 3.0mg

Common side effects: Nausea, diarrhoea, constipation, headache, hypoglycaemia (particularly in combination with other diabetes medications)

Note: Saxenda is older and produces less weight loss than newer options. Many physicians now prefer semaglutide or tirzepatide when available.

Important Considerations Before Starting

These Are Long-Term Treatments

These medications require ongoing use to maintain weight loss. Data from the STEP 4 trial (semaglutide) found that participants who discontinued the drug after 68 weeks regained approximately two-thirds of their lost weight within one year. This means injectable weight loss medications are a long-term commitment, not a course of treatment.

Side Effects Are Common

Gastrointestinal side effects — particularly nausea in the first 4–8 weeks of each dose increase — affect the majority of patients to some degree. Most find these manageable with dose titration, eating smaller portions, and avoiding high-fat meals.

Rare but serious reported risks include:

Pancreatitis
Gallbladder disease (cholelithiasis)
Heart rate increase (semaglutide and tirzepatide)
Contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2

They Must Be Prescribed

All three medications require a prescription and medical supervision. They are not available over the counter.

Insurance Coverage Varies

Coverage for Wegovy and Zepbound varies significantly by insurer and country. Many US insurance plans do not cover anti-obesity medications, making out-of-pocket costs substantial ($900–1,400/month at full price, though manufacturer coupons and savings programmes can reduce this considerably).

Lifestyle Modification Is Still Required

Clinical trials of all three medications included structured dietary and physical activity interventions. The medications work most effectively — and produce better long-term outcomes — when combined with meaningful lifestyle changes rather than used as standalone treatments.

What About Non-Injectable FDA-Approved Weight Loss Medications?

For completeness, FDA-approved oral options include:

Orlistat (Alli/Xenical) — lipase inhibitor
Phentermine/topiramate (Qsymia) — combination appetite suppressant
Naltrexone/bupropion (Contrave) — appetite/reward pathway medication
Phentermine alone — short-term use only (12 weeks)

These generally produce less weight loss than the injectable GLP-1/GIP agonists and may suit people who prefer oral administration.

Conclusion

As of 2025, the FDA-approved injectable weight loss medications are semaglutide (Wegovy), tirzepatide (Zepbound), and liraglutide (Saxenda). Tirzepatide produces the greatest average weight loss (approximately 21% of body weight), followed by semaglutide (approximately 15%), and liraglutide (approximately 8%). All require prescription, medical supervision, and ongoing use to maintain results. They are not appropriate for everyone — a thorough medical evaluation is essential before starting any of these treatments.

Disclaimer: This article is for informational and educational purposes only and does not constitute medical advice. These are prescription medications that should only be used under the supervision of a qualified healthcare provider. Always discuss the benefits and risks with your doctor before starting any weight loss medication.